Source 1primary paper2025MED
Toolkit/CRISPR/Cas with long-acting slow-effective release antiretroviral therapy
CRISPR/Cas with long-acting slow-effective release antiretroviral therapy
Also known as: CRISPR/Cas along with long-acting slow-effective release antiretroviral therapy
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Precision genome editing can be achieved by using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) along with long-acting slow-effective release antiretroviral therapy.
Usefulness & Problems
Why this is useful
The abstract presents CRISPR/Cas used together with long-acting slow-effective release antiretroviral therapy as a precision genome editing strategy for HIV-1 cure efforts. It is framed as one component of a multimodal combination approach.; precision genome editing in HIV-1 cure strategies
Source:
The abstract presents CRISPR/Cas used together with long-acting slow-effective release antiretroviral therapy as a precision genome editing strategy for HIV-1 cure efforts. It is framed as one component of a multimodal combination approach.
Source:
precision genome editing in HIV-1 cure strategies
Problem solved
It addresses the need for precision genome editing within HIV-1 cure strategies.; adding a genome editing modality to multimodal HIV-1 cure approaches
Source:
It addresses the need for precision genome editing within HIV-1 cure strategies.
Source:
adding a genome editing modality to multimodal HIV-1 cure approaches
Problem links
adding a genome editing modality to multimodal HIV-1 cure approaches
LiteratureIt addresses the need for precision genome editing within HIV-1 cure strategies.
Source:
It addresses the need for precision genome editing within HIV-1 cure strategies.
Published Workflows
Objective: Develop an HIV-1 cure framework that combines neutralizing antibodies, precision genome editing, and latent reservoir management rather than relying on monotherapy.
Why it works: The abstract argues that combining complementary modalities can address limitations of ART and monotherapies by jointly targeting viral replication, latent reservoirs, and immune dysfunction.
induction of broadly neutralizing antibodiesprecision genome editinglatent virus reactivationimmune clearanceimmune system reconstitutionreversal of T-cell exhaustionEnv trimer vaccinationmRNA-lipid nanoparticle deliveryCRISPR/Cas genome editingshock and killCAR-T cell therapybispecific antibody therapystem cell transplantationimmune checkpoint inhibition
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A composed arrangement of multiple parts that instantiates one or more mechanisms.
Techniques
Computational DesignTarget processes
editingImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: multi component delivery burdenoperating role: regulatorswitch architecture: multi component
This approach requires CRISPR/Cas gene editing tools and a long-acting slow-effective release ART component.; requires improved targeting specificity of CRISPR systems; delivery of gene editing tools is inefficient
The abstract notes that gene editing tools still face off-target effects and inefficient delivery.; off-target effects; inefficient delivery of gene editing tools
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
CAR-T cells and bispecific antibodies are engineered therapeutic modalities for subsequent immune clearance in HIV-1 cure strategies.
Engineered cellular therapies include chimeric antigen receptor T (CAR-T) cells or bispecific antibodies (bsAbs) for subsequent immune clearance
Current multimodal HIV-1 cure strategies face challenges including suboptimal Env vaccine immunogenicity, off-target effects and inefficient delivery of gene editing tools, incomplete latent virus reactivation, and limitations of preclinical models.
Despite these advances, challenges remain, including suboptimal immunogenicity of Env vaccines, off-target effects and inefficient delivery of gene editing tools, incomplete reactivation of latent viruses, and limitations of preclinical models.
Future work should optimize synergistic effects by improving Env trimer design, enhancing CRISPR targeting specificity, and developing preclinical models that better reflect human immunity.
Future research should focus on optimizing synergistic effects by improving Env trimer design, enhancing the targeting specificity of CRISPR systems, and developing preclinical models that more accurately reflect human immunity
ART suppresses HIV-1 replication but cannot eliminate latent viral reservoirs and has limitations including lifelong treatment need and risk of drug resistance.
Despite its potency in suppressing HIV-1 replication, antiretroviral therapy (ART) cannot eliminate latent viral reservoirs and is associated with several limitations, such as the need for lifelong treatment and the inherent risk of drug resistance.
Native-like Env trimer vaccines are used to induce broadly neutralizing antibodies in HIV-1 antibody-based interventions.
Antibody-based interventions primarily involve inducing broadly neutralizing antibodies (bNAbs) through native-like envelope (Env) trimer vaccines
Precision genome editing for HIV-1 cure can be achieved using CRISPR/Cas together with long-acting slow-effective release antiretroviral therapy.
Precision genome editing can be achieved by using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) along with long-acting slow-effective release antiretroviral therapy.
Reservoir-targeted therapies are typically implemented by reactivating latent viruses using the shock and kill strategy.
Reservoir-targeted therapies are typically implemented by reactivating latent viruses using the "shock and kill" strategy.
mRNA-lipid nanoparticle delivery systems further enhance the efficacy of Env trimer vaccine-based antibody interventions.
with their efficacy further enhanced by mRNA-lipid nanoparticle delivery systems
The HIV-1 cure field has progressed from monotherapy to multimodal combination strategies including neutralizing antibodies, precision genome editing, and latent reservoir management.
The quest for an HIV-1 cure has progressed from monotherapeutic approaches to the combinations of multimodal strategies, including neutralizing antibodies, precision genome editing, and management of latent reservoirs.
Approval Evidence
1 source4 linked approval claimsfirst-pass slug crispr-cas-with-long-acting-slow-effective-release-antiretroviral-therapy
Precision genome editing can be achieved by using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) along with long-acting slow-effective release antiretroviral therapy.
Source:
challengesupports
Current multimodal HIV-1 cure strategies face challenges including suboptimal Env vaccine immunogenicity, off-target effects and inefficient delivery of gene editing tools, incomplete latent virus reactivation, and limitations of preclinical models.
Despite these advances, challenges remain, including suboptimal immunogenicity of Env vaccines, off-target effects and inefficient delivery of gene editing tools, incomplete reactivation of latent viruses, and limitations of preclinical models.
Source:
future directionsupports
Future work should optimize synergistic effects by improving Env trimer design, enhancing CRISPR targeting specificity, and developing preclinical models that better reflect human immunity.
Future research should focus on optimizing synergistic effects by improving Env trimer design, enhancing the targeting specificity of CRISPR systems, and developing preclinical models that more accurately reflect human immunity
Source:
mechanism or functionsupports
Precision genome editing for HIV-1 cure can be achieved using CRISPR/Cas together with long-acting slow-effective release antiretroviral therapy.
Precision genome editing can be achieved by using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) along with long-acting slow-effective release antiretroviral therapy.
Source:
strategy frameworksupports
The HIV-1 cure field has progressed from monotherapy to multimodal combination strategies including neutralizing antibodies, precision genome editing, and latent reservoir management.
The quest for an HIV-1 cure has progressed from monotherapeutic approaches to the combinations of multimodal strategies, including neutralizing antibodies, precision genome editing, and management of latent reservoirs.
Source:
Comparisons
Source-stated alternatives
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Source:
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Source-backed strengths
presented as a route to precision genome editing
Source:
presented as a route to precision genome editing
Compared with bispecific antibodies
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as a route to precision genome editing.
Relative tradeoffs: off-target effects; inefficient delivery of gene editing tools.
Source:
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Compared with CAR-T
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as a route to precision genome editing.
Relative tradeoffs: off-target effects; inefficient delivery of gene editing tools.
Source:
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Compared with CAR-T cells
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as a route to precision genome editing.
Relative tradeoffs: off-target effects; inefficient delivery of gene editing tools.
Source:
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Compared with CAR-T cell therapy
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as a route to precision genome editing.
Relative tradeoffs: off-target effects; inefficient delivery of gene editing tools.
Source:
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Compared with CAR-T therapy
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as a route to precision genome editing.
Relative tradeoffs: off-target effects; inefficient delivery of gene editing tools.
Source:
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Compared with Chimeric Antigen Receptor (CAR) T-cell therapy
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as a route to precision genome editing.
Relative tradeoffs: off-target effects; inefficient delivery of gene editing tools.
Source:
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Compared with chimeric antigen receptor T cells
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as a route to precision genome editing.
Relative tradeoffs: off-target effects; inefficient delivery of gene editing tools.
Source:
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Compared with Chimeric antigen receptor T-cell therapy
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as a route to precision genome editing.
Relative tradeoffs: off-target effects; inefficient delivery of gene editing tools.
Source:
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Compared with native-like Env trimer vaccines
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as a route to precision genome editing.
Relative tradeoffs: off-target effects; inefficient delivery of gene editing tools.
Source:
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Compared with stem cell transplantation
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as a route to precision genome editing.
Relative tradeoffs: off-target effects; inefficient delivery of gene editing tools.
Source:
The abstract contrasts this approach with bNAb induction via Env trimer vaccines, shock-and-kill reservoir management, CAR-T cells, bispecific antibodies, stem cell transplantation, and immune checkpoint inhibitors.
Ranked Citations